Exploring lincRNA's Role in Breast Cancer
Fox Chase researchers identify abnormally expressed lincRNAs in breast cancer patients, establishing a new path for understanding how cancer works
WASHINGTON, DC (April 8, 2013)—Once considered part of the “junk” of our genome, much of the DNA between protein-coding genes is now known to be transcribed. New findings by scientists at Fox Chase Cancer Center have identified several dozen transcripts known as lincRNAs, or long intergenic non-coding RNAs, that are dysregulated in breast cancer. The results, to be presented at the AACR Annual Meeting 2013 on Monday, April 8, offer both a new research path for better understanding of how breast cancer works and a new method for identifying lincRNAs that may contribute to tumorigenesis or regulation of other cancers.
“This is a very preliminary result,” says study author Xiaowei Chen, PhD, assistant professor at Fox Chase, “because we spent most of our time trying to define how to pull out the useful information” from the region of the genome between protein-coding genes. Even though “the overall concept is new,” says Chen, in the end the team settled on standard methods for each step of the genome-wide approach for identifying lincRNA-coding regions.
In the study, researchers conducted pairwise comparisons of genomic information between five tumor samples and the adjacent normal cells. That comparison yielded 47 lincRNA transcripts, of which the team selected the most prevalent 14. They then checked how these lincRNAs were expressed by 12 established breast cancer cell lines and four non-cancerous cell lines. The team found that expression varied widely, indicating that lincRNAs are differentially regulated within breast cancer cell lines.
“We wanted to identify the changes in order to find some candidates,” says Chen, rather than identify all candidates; “there are many more, I believe.”
The next step will be to conduct a functional analysis of these 14 most prevalent transcripts to see if the expression has any biological meaning. Already, the team has identified one lincRNA gene that Chen says “looks pretty promising,” but full results will come later.
Co-authors on the study include Zhengyu Jiang, Yan Zhou, Karthik Devarajan, Carolyn M. Slater, and Mary B. Daly of Fox Chase.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.